



08/31/01

GAU 1648

PATENT

Docket No. 2026-4116US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Bukh, et al. Group Art Unit : 1648
Serial No. : 09/084,691 Examiner : Zeman, M.
Filed : May 26, 1998
For : NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF THE
ENVELOPE 1 AND CORE GENES OF ISOLATES OF HEPATITIS C
VIRUS AND THE USE OF REAGENTS DERIVED FROM THESE
SEQUENCES IN DIAGNOSTIC METHODS AND VACCINES

RECEIVED

SEP 05 2001

TECH CENTER 1600/2900

EXPRESS MAIL CERTIFICATE

Express Mail Label: EL 911999401 US
Date of Deposit: August 30, 2001
Commissioner for Patents
Washington, D.C. 20231

Sir:

I hereby certify that the attached

1. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures
2. Disk - computer readable form
3. Paper Copy of Sequence Listing - 201 pages
4. Statement under 37 CFR 1.821(f) or 1.826(b)
5. Response Fee Transmittal
6. Return postcard

is being deposited with the United States Postal Service "Express Mail Post Office to addressee" service under 37


CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: August 30, 2001

By:


Jesus R. Remedios

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN LLP
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 Facsimile



PATENT

Docket No. 2026-4116US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Bukh, et al.

Serial No : 09/084,691

Group Art Unit: 1648

Filed : May 26, 1998

Examiner: Zeman, M.

For : **NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF THE
ENVELOPE 1 AND CORE GENES OF ISOLATES OF HEPATITIS C VIRUS
AND THE USE OF REAGENTS DERIVED FROM THESE SEQUENCES IN
DIAGNOSTIC METHODS AND VACCINES**

RECEIVED
SEP 05 2001
TECH CENTER 1600/2900

RESPONSE FEE TRANSMITTAL

COMMISSIONER OF PATENTS
Washington, D.C. 20231

Sir:

Transmitted herewith is a Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated August 1, 2001 for the above-identified application.

☒ No additional fee is required.

☐ The additional fee has been calculated as shown below:

CLAIMS AS AMENDED

Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Present Extra	Rate	Additional Fee
Total* Claims	-	= 0	x \$18.00	<u>\$0.00</u>
Independent Claims	-	= 0	x \$78.00	<u>\$0.00</u>

* Includes all independent and single dependent claims and all claims referred to in multiple dependent claims. See 37 C.F.R. § 1.75(c).

Multiple Dependent Claim(s)	(If claims added by amendment include Multiple Dependent Claim(s) and there was not Multiple Dependent Claims(s) in application before amendment add \$260.00 to additional fee.)	\$ <u>0.00</u>
Total:		\$ <u>0.00</u>

[] Statement of "Small Entity" Status Under 37 CFR § 1.27 filed _____.
Reduced Fees Under 37 CFR § 1.9(f) (50% of total) paid herewith. \$ _____.

[] Charge fee to Deposit Account No. 13-4500. Order No. _____.
A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

[X] The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for this amendment, including all fees pursuant to 37 C.F.R. § 1.17 for its timely consideration, or credit any overpayment to Deposit Account No. 13-4500. Order No. 2026-4116US2. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

[X] 201 Page(s) of substitute Sequence Listing

[X] 1 Computer disk(s) containing substitute Sequence Listing

[X] Statement under 37 C.F.R. § 1.825(b) that the computer and paper copies of the substitute Sequence Listing are the same.

[] A check in the amount of \$ _____ to cover the filing fee is attached.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: August 30, 2001

By: William S. Feiler
William S. Feiler
Registration No. 26,728

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 Facsimile

FORM: AMD-TRAN.NY
Rev. 11/13/98